Top-Rated StocksTop-RatedNASDAQ:IPSC Century Therapeutics (IPSC) Stock Forecast, Price & News $3.38 +0.18 (+5.63%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$3.19▼$3.4350-Day Range$2.91▼$3.5352-Week Range$2.81▼$14.00Volume127,674 shsAverage Volume160,172 shsMarket Capitalization$201.38 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Century Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside462.1% Upside$19.00 Price TargetShort InterestBearish6.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$295,202 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.07) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector827th out of 981 stocksBiological Products, Except Diagnostic Industry128th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Century Therapeutics has a forecasted upside of 462.1% from its current price of $3.38.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.18% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 0.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,202.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.81% of the stock of Century Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($2.07) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Century Therapeutics (NASDAQ:IPSC) StockCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSC Stock News HeadlinesMay 26, 2023 | americanbankingnews.comBrokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Target Price at $19.00May 12, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Century Therapeutics (IPSC)June 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | finance.yahoo.comCentury Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 11, 2023 | msn.comCentury Therapeutics: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 11, 2023 | finance.yahoo.comCentury Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2023 | finance.yahoo.comCentury Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesJune 7, 2023 | Altimetry (Ad)Biden's latest bailout--terrible for America?And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—May 1, 2023 | americanbankingnews.comAnalysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $19.00April 19, 2023 | americanbankingnews.comEF Hutton Acquisition Co. I Reiterates "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)April 17, 2023 | benzinga.comCentury Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual SummitApril 13, 2023 | msn.comHC Wainwright & Co. Reiterates Century Therapeutics (IPSC) Buy RecommendationApril 13, 2023 | markets.businessinsider.comAnalyst Ratings for Century TherapeuticsApril 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Brainsway (BWAY) and Century Therapeutics (IPSC)April 12, 2023 | msn.comCentury Therapeutics CEO Lalo Flores steps down, Greg Russotti appointed as ad-interim Chief Executive OfficerApril 12, 2023 | bizjournals.comCentury Therapeutics CEO departs amid shakeup in C-suiteApril 12, 2023 | finance.yahoo.comCentury Therapeutics Announces Leadership ChangesMarch 29, 2023 | americanbankingnews.comFY2023 EPS Estimates for Century Therapeutics, Inc. (NASDAQ:IPSC) Boosted by Chardan CapitalMarch 25, 2023 | americanbankingnews.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Insider Luis Borges Sells 15,597 SharesMarch 22, 2023 | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)March 22, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for Century Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:IPSC)March 22, 2023 | americanbankingnews.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Forecasted to Post Q1 2024 Earnings of ($0.48) Per ShareMarch 21, 2023 | markets.businessinsider.comChardan Capital Sticks to Their Buy Rating for Century Therapeutics (IPSC)March 21, 2023 | americanbankingnews.comBank of America Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $20.00March 20, 2023 | msn.comCentury Therapeutics's Return On Capital Employed OverviewMarch 16, 2023 | markets.businessinsider.comEF Hutton Sticks to Their Buy Rating for Century Therapeutics (IPSC)See More Headlines IPSC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Company Calendar Last Earnings3/16/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+462.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,930,000.00 Net Margins-2,127.33% Pretax Margin-2,105.44% Return on Equity-39.33% Return on Assets-25.10% Debt Debt-to-Equity RatioN/A Current Ratio9.24 Quick Ratio9.24 Sales & Book Value Annual Sales$5.20 million Price / Sales38.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book0.66Miscellaneous Outstanding Shares59,580,000Free Float55,053,000Market Cap$201.38 million OptionableNot Optionable Beta0.59 Key ExecutivesDr. Osvaldo Flores Ph.D. (Age 59)Pres, CEO & Director Comp: $778.06kDr. Adrienne Farid Ph.D. (Age 60)Chief Operations Officer Comp: $589.47kDr. Luis Borges (Age 60)Chief Scientific Officer Comp: $604.12kMr. Douglas Carr CPAVP of Fin. and Operations & Sec.Dr. Gregory Russotti Ph.D. (Age 55)Chief Technology Officer Mr. Kenneth J. Dow J.D.Head of Legal & ComplianceDr. Shane Williams Ph.D.Chief People OfficerDr. Michael C. Diem (Age 51)Chief Bus. Officer Dr. Hyam I. Levitsky M.D. (Age 64)Pres of R&D Mr. Mark WalletHead of Immunology & VPMore ExecutivesKey CompetitorsOptheaNASDAQ:OPTBioAtlaNASDAQ:BCABJasper TherapeuticsNASDAQ:JSPRPoseida TherapeuticsNASDAQ:PSTXGraphite BioNASDAQ:GRPHView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 18,625 shares on 5/22/2023Ownership: 0.031%New York State Common Retirement FundBought 5,966 shares on 5/18/2023Ownership: 0.033%Geode Capital Management LLCBought 11,448 shares on 5/16/2023Ownership: 0.707%Jane Street Group LLCBought 14,482 shares on 5/16/2023Ownership: 0.024%Susquehanna International Group LLPSold 19,553 shares on 5/16/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions IPSC Stock - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price forecast for 2023? 9 equities research analysts have issued 12 month price objectives for Century Therapeutics' shares. Their IPSC share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 462.1% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2023? Century Therapeutics' stock was trading at $5.13 on January 1st, 2023. Since then, IPSC stock has decreased by 34.1% and is now trading at $3.38. View the best growth stocks for 2023 here. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings data on Thursday, March, 16th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.80 million. Century Therapeutics had a negative net margin of 2,127.33% and a negative trailing twelve-month return on equity of 39.33%. When did Century Therapeutics IPO? (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO. What is Century Therapeutics' stock symbol? Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC." Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (8.97%), BlackRock Inc. (2.37%), Geode Capital Management LLC (0.71%), State Street Corp (0.62%), Renaissance Technologies LLC (0.26%) and New York Life Investment Management LLC (0.22%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Century Therapeutics' stock price today? One share of IPSC stock can currently be purchased for approximately $3.38. How much money does Century Therapeutics make? Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $201.38 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. How many employees does Century Therapeutics have? The company employs 170 workers across the globe. How can I contact Century Therapeutics? The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com. This page (NASDAQ:IPSC) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.